Table 1.
Description of the patients
| Discovery Set | Validation Set | ||||
|---|---|---|---|---|---|
| Italian cases of COVID-19 | Spanish cases of other pneumonia | American cases of other pneumonia | World cases of COVID-19 | World cases ofother pneumonia | |
| (n = 29) | (n = 127) | (n = 39) | (n = 20) | (n = 12) | |
| Age* | 61.1 ± 13.2 | 63.1 ± 18.1 | NA | 48.6 ± 14.8 | 49.5 ± 17.4 |
| (27–87) | (29–99) | (12–71) | (25–74) | ||
| Gender | |||||
| Female | 10 | 49 | NA | 8 | 5 |
| Male | 19 | 78 | NA | 9 | 5 |
| Chest abnormalities | |||||
| Airspace disease | - | - | 13 | 1 | - |
| Aortic changes | - | 24 | 2 | - | - |
| Cardiomegaly | - | 17 | - | - | 1 |
| Consolidation | 3 | 2 | 9 | 7 | 6 |
| Heart insufficiency | - | 10 | - | - | - |
| Hilar enlargement | 1 | 7 | - | - | - |
| Infiltrate | - | 6 | 4 | 2 | - |
| Pleural effusion | 2 | 11 | 4 | 1 | - |
| Pleural thickening | - | 6 | - | 1 | - |
| Pulmonary atelectasis | - | 11 | 5 | - | - |
| Pulmonary emphysema | - | 2 | 1 | - | - |
| Pulmonary fibrosis | - | 2 | - | - | - |
NA, not available
* Mean ± standard deviation (min–max)